Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Amicus Ends Lead Rare Disease Drug Program

Amicus Therapeutics terminated a late-stage wound-treatment therapeutic after it failed to meet primary and secondary endpoints in a Phase III trial.

Read More »

Mylan says Allergan misusing tribal sovereignty in patent dispute

Generic drugmaker Mylan NV alleged in a court filing that rival Allergan Plc is trying to take advantage of Native American sovereignty to shield its patent for the blockbuster dry-eye treatment Restasis.

Read More »

Two Deaths Hit AbbVie’s Late-Stage RA Study

AbbVie announced positive top-line results from its Phase III clinical trial of upadacitinib (ABT-494) in moderate-to-severe rheumatoid arthritis patients.

Read More »

J&J Ends Hep C Drug Program

Janssen Sciences Ireland UC, a Johnson & Johnson company, announced the decision to halt development of its hepatitis C treatment combination JNJ-4178.

Read More »

Cancer immunotherapy proves itself in earlier-stage disease

Cancer doctors are widening the net for immunotherapy, a hot new class of drugs that enlist the body’s defenses in the fight against tumors.

Read More »

AstraZeneca rebuilds cancer drug hopes with new lung data

Two AstraZeneca drugs tackling lung cancer in different ways delivered impressive clinical results on Saturday, helping the British group offset July 2017’s big clinical trial setback in the disease.

Read More »

Death puts Cellectis cell therapy tests on hold

French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment, was forced to suspend testing following a patient death.

Read More »

Incyte Discloses Promising New Data in Combo Drug Trial With Merck & Co.’s Keytruda

Incyte Corporation will have an abstract published at the European Society for Medical Oncology (ESMO) meeting in early September with new and updated data from its ongoing Phase I/II trial of epacadostat in combination with Merck & Co.’s Keytruda in advanced melanoma.

Read More »

Daiichi Sankyo denies AstraZeneca takeover bid

Japanese drugmaker Daiichi Sankyo denied that it received a takeover bid during 2016 from Britain’s AstraZeneca.

Read More »

Otonomy pulls plug on ear drug, shares nosedive

Otonomy Inc. suspended developing its drug for Meniere’s disease, a chronic disorder of the inner ear, after it failed a late-stage trial.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom